/
AURA
$7.65-$0.10 (-1.29%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$801.6M
103M shares
52-week range
$4.73 – $9.54
61% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-7.15
Aura Biosciences, Inc. Common Stock
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
www.aurabiosciences.com- Employees
- 113
- IPO / List date
- Oct 29, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AURA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 102,100 | $683.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AURA yet.
